Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XTNT
stocks logo

XTNT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
31.75M
+0.75%
-0.005
-87.5%
28.50M
-13.38%
-0.005
-75%
Estimates Revision
The market is revising Upward the revenue expectations for Xtant Medical Holdings, Inc. (XTNT) for FY2025, with the revenue forecasts being adjusted by 2.57% over the past three months. During the same period, the stock price has changed by -3.13%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.57%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+150%
In Past 3 Month
Stock Price
Go Down
down Image
-3.13%
In Past 3 Month
Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.610
sliders
Low
1.50
Averages
1.50
High
1.50
Current: 0.610
sliders
Low
1.50
Averages
1.50
High
1.50
BTIG
Buy
downgrade
$2
2025-11-11
Reason
BTIG
Price Target
$2
2025-11-11
downgrade
Buy
Reason
BTIG lowered the firm's price target on Xtant Medical to $1.50 from $2 and keeps a Buy rating on the shares. Xtant Medical reported Q3 revenue up 19% year over year and EPS of 1c, slightly above estimates, driven by $5.5M in license revenue, the analyst tells investors in a research note. The company reaffirmed FY25 guidance of $131M-$135M and appears positioned for self-sustained growth, with high single-digit expansion expected in FY26 and beyond, BTIG says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Xtant Medical Holdings Inc (XTNT.A) is -122.06, compared to its 5-year average forward P/E of -12.26. For a more detailed relative valuation and DCF analysis to assess Xtant Medical Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.26
Current PE
-122.06
Overvalued PE
18.77
Undervalued PE
-43.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
21.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
41.68
Undervalued EV/EBITDA
1.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.03
Current PS
0.00
Overvalued PS
1.73
Undervalued PS
0.33
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

XTNT News & Events

Events Timeline

(ET)
2025-11-10
16:30:34
Xtant Medical announces Q3 earnings per share of 1 cent compared to a loss of 4 cents last year.
select
2025-04-16 (ET)
2025-04-16
08:06:25
Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Businesswire
Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach
  • Acquisition Completed: Companion Spine has finalized its acquisition of Paradigm Spine, integrating the Coflex® and CoFix® implants, which is expected to enhance its competitive edge in the spine implant market and increase market share to meet global demand.
  • Leadership Integration: The new company will be led by Anthony G. Viscogliosi as Executive Chairman and CEO, with Enrico Sangiorgio as Executive Vice President International, ensuring stability in leadership and capability for market expansion.
  • Expanded Product Portfolio: The combined product offerings include various spinal stabilization solutions that cater to a range of conditions, which is anticipated to improve customer satisfaction and strengthen partnerships with distributors.
  • Market Strategy Overhaul: Companion Spine will focus on the U.S. market, leveraging its FDA-approved product portfolio to enhance physician awareness of SMART™ technologies, thereby optimizing patient treatment outcomes and driving long-term growth for the company.
[object Object]
Preview
7.5
12-02Newsfilter
Xtant Medical Sells Non-Core Assets for $19.2 Million
  • Asset Sale: Xtant Medical has completed the sale of its Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine for approximately $19.2 million, consisting of $11 million in cash and $8.2 million in short-term seller financing, which is expected to enhance the company's financial liquidity.
  • Debt Reduction: The net proceeds from this transaction will be used to reduce long-term debt, enabling Xtant Medical to continue operations without the need for additional external capital, thereby strengthening the company's financial stability.
  • Focus on Core Business: CEO Sean Browne stated that this asset sale represents a significant step in allowing the company to concentrate on its core biologics business, driving innovation and improving financial performance, reflecting the company's commitment to strategic transformation.
  • Operational Contribution: The operating contributions of these assets and entities will be included in the company's results through the December 1, 2025 date of sale, indicating the company's continued valuation of these businesses prior to the sale.
[object Object]
Preview
9.5
08-12NASDAQ.COM
Xtant Medical Holdings, Inc Q2 Earnings Summary

  • Earnings Performance: Xtant Medical Holdings, Inc reported earnings of $3.55 million in Q2, a significant improvement from a loss of $3.86 million in the same period last year, with an EPS of $0.02 compared to -$0.03 previously.

  • Revenue Growth and Guidance: The company achieved revenue of $35.41 million in Q2, up from $29.94 million year-over-year, and provided full-year revenue guidance of $131 - $135 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xtant Medical Holdings Inc (XTNT) stock price today?

The current price of XTNT is 0.6103 USD — it has increased 2.01 % in the last trading day.

arrow icon

What is Xtant Medical Holdings Inc (XTNT)'s business?

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

arrow icon

What is the price predicton of XTNT Stock?

Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xtant Medical Holdings Inc (XTNT)'s revenue for the last quarter?

Xtant Medical Holdings Inc revenue for the last quarter amounts to 33.26M USD, increased 19.04 % YoY.

arrow icon

What is Xtant Medical Holdings Inc (XTNT)'s earnings per share (EPS) for the last quarter?

Xtant Medical Holdings Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xtant Medical Holdings Inc (XTNT)'s fundamentals?

The market is revising Upward the revenue expectations for Xtant Medical Holdings, Inc. (XTNT) for FY2025, with the revenue forecasts being adjusted by 2.57% over the past three months. During the same period, the stock price has changed by -3.13%.
arrow icon

How many employees does Xtant Medical Holdings Inc (XTNT). have?

Xtant Medical Holdings Inc (XTNT) has 217 emplpoyees as of December 05 2025.

arrow icon

What is Xtant Medical Holdings Inc (XTNT) market cap?

Today XTNT has the market capitalization of 85.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free